Delivery of Grem1 neutralising antibodies that inhibit Grem1 binding to target Bmps to in vivo mouse models of pancreatic cancer would allow investigators to assess whether this leads to improved or worsened tumor volume and outcomes. The gene discussed is CLN5; the disease is familial pancreatic carcinoma.